These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 2900217

  • 1. The electrophysiologic properties of esmolol, a short acting beta-blocker.
    Greenspan AM, Spielman SR, Horowitz LN, Laddu A, Senior S.
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):209-16. PubMed ID: 2900217
    [Abstract] [Full Text] [Related]

  • 2. Electrophysiology of esmolol.
    Greenspan AM, Spielman SR, Horowitz LN, Senior S, Steck J, Laddu A.
    Am J Cardiol; 1985 Oct 23; 56(11):19F-26F. PubMed ID: 2864844
    [Abstract] [Full Text] [Related]

  • 3. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH, Shettigar UR, Appunn DO.
    Int J Clin Pharmacol Ther; 1995 Apr 23; 33(4):212-8. PubMed ID: 7620691
    [Abstract] [Full Text] [Related]

  • 4. Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker.
    Swerdlow CD, Peterson J, Turlapaty P.
    Am Heart J; 1986 Jan 23; 111(1):49-53. PubMed ID: 2868646
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM, Schultz NJ, Tschida VH.
    Clin Pharm; 1986 Apr 23; 5(4):288-303. PubMed ID: 2871961
    [Abstract] [Full Text] [Related]

  • 7. [Electrophysiologic effects of betaxolol on conduction properties of the antegrade and retrograde pathway in patients with typical atrioventricular node reentry tachycardia following intravenous and oral administration].
    Kühlkamp V, Ickrath O, Haasis R, Seipel L.
    Z Kardiol; 1988 Aug 23; 77(8):527-33. PubMed ID: 3176596
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of electrophysiologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia.
    Gambhir DS, Bhargava M, Nair M, Arora R, Khalilullah M.
    Indian Heart J; 1996 Aug 23; 48(2):133-7. PubMed ID: 8682552
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Esmolol in the treatment of supraventricular tachyarrhythmias.
    Das G, Ferris J.
    Can J Cardiol; 1988 May 23; 4(4):177-80. PubMed ID: 2899451
    [Abstract] [Full Text] [Related]

  • 18. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol.
    Sugiyama A, Takahara A, Hashimoto K.
    J Cardiovasc Pharmacol; 1999 Jul 23; 34(1):70-7. PubMed ID: 10413070
    [Abstract] [Full Text] [Related]

  • 19. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent.
    Bessho R, Chambers DJ.
    J Thorac Cardiovasc Surg; 2001 Nov 23; 122(5):993-1003. PubMed ID: 11689806
    [Abstract] [Full Text] [Related]

  • 20. Esmolol: a short-acting titratable beta-blocker in acute myocardial ischemia.
    Viray R, Turlapaty P, Laddu A.
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar 23; 26(3):153-61. PubMed ID: 2900818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.